American Society of Hematology

Figure 5

$Figure 5. Placental ex vivo transport of wild-type IgG1 and engineered antibody. Antibodies were added to the maternal side in pairs of 1 wild-type and 1 engineered antibody. Medium fractions were collected from the fetal and maternal side at the indicated time points. Measurement of the concentration of antibody was done with an ELISA with the antigen for α-MSP-3 and in SOL-ELISA with D-positive RBCs for α-D, respectively. No difference was found in the placental transport kinetics of (A) α-MSP-3,IgG1 and α-D,IgG1, (B) α-D,IgG1 and α-MSP-3,IgG3, and (D) α-MSP-3,IgG1 and IgG3ΔHinge:R435H. In contrast, the fetal concentration of (C) IgG3ΔHinge was not significantly different from 0 µg/mL at any time point during the perfusion, demonstrating lack of transport.$

Placental ex vivo transport of wild-type IgG1 and engineered antibody. Antibodies were added to the maternal side in pairs of 1 wild-type and 1 engineered antibody. Medium fractions were collected from the fetal and maternal side at the indicated time points. Measurement of the concentration of antibody was done with an ELISA with the antigen for α-MSP-3 and in SOL-ELISA with D-positive RBCs for α-D, respectively. No difference was found in the placental transport kinetics of (A) α-MSP-3,IgG1 and α-D,IgG1, (B) α-D,IgG1 and α-MSP-3,IgG3, and (D) α-MSP-3,IgG1 and IgG3ΔHinge:R435H. In contrast, the fetal concentration of (C) IgG3ΔHinge was not significantly different from 0 µg/mL at any time point during the perfusion, demonstrating lack of transport.

This Feature Is Available To Subscribers Only